Teva is planning to reduce its headcount by 8% by 2027, the company announced on Wednesday, as it enters the next phase of ...

A leading pharmaceutical trade group urged the Department of Commerce not to place tariffs on the sector as the window for ...

Federal appeals court overturns order blocking Avadel Pharmaceuticals from seeking FDA approval for Lumryz in idiopathic ...

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

NewAmsterdam's obicetrapib reduced Lp(a) by 45% in Phase 3; C4 Therapeutics advances cemsidomide while dropping CFT1946; Vivo ...

Los Angeles-based health system Cedars-Sinai is partnering with venture studio Redesign Health to build health tech startups ...

Theriva Biologics' VCN-01 plus chemotherapy showed improved survival in pancreatic cancer patients vs. chemo alone in Phase ...

How did biopharma stocks react to Vinay Prasad’s appointment as director of one of the FDA's top jobs? Not well. Prasad, a ...

Marea Therapeutics said on Wednesday that its lipid-lowering antibody cut both remnant cholesterol levels and remnant ...

Sarepta's stock falls 48% after FDA critic Vinay Prasad's appointment and poor Elevidys sales. Company cuts revenue forecast ...

Attorneys general from 19 states and Washington, DC have filed a lawsuit against the federal government alleging that its ...

NewLimit raises $130M Series B led by Kleiner Perkins to advance epigenetic reprogramming research for liver disease ...